Category: Hepatology

According to a Cochrane systematic review, tacrolimus is superior to cyclosporine in preventing acute rejection after liver transplantation. So, what medication is used for liver rejection? Transplant patients rely on a combination of powerful immunosuppressive drugs to prevent their body from attacking the new organ.

According to recent guidelines presented at Digestive Disease Week 2025, a paradigm shift is underway in the management of portal hypertension, with a stronger endorsement of carvedilol as a preferred medication. While no single medication has been designated definitively as "what is the new drug for portal hypertension?", research is actively focused on targeted therapies and optimizing existing treatments.

In the United States, the prevalence of cirrhosis is approximately 2.6%, with clinically significant portal hypertension affecting nearly 1% of the general population [1.9.1]. The cornerstone of medical management for this condition is pharmacotherapy, so a key question is: what is the drug of choice for portal hypertension? [1.2.5, 1.3.1]

According to extensive meta-analysis, non-selective beta-blockers like propranolol can reduce the risk of a first variceal bleeding episode by about 50% in high-risk patients. This remarkable efficacy demonstrates **why propranolol helps with varices** by addressing the underlying cause of high pressure in the portal venous system.

According to a 2025 review, patients with underlying chronic liver diseases like Primary Biliary Cholangitis (PBC) have an increased risk for drug-induced liver injury, making it vital to know **what drugs should be avoided with PBC**. Navigating medications safely is crucial for managing the disease and preventing complications, including progression to cirrhosis.

In June 2024, Iqirvo (elafibranor) received accelerated approval from the FDA, offering a new treatment option for adults with primary biliary cholangitis (PBC). For those searching for information, it is important to note that the medication is spelled 'Iqirvo,' and this guide answers the question of what does Icarvo treat by detailing the correct medication.

Losartan is a widely prescribed angiotensin II receptor blocker for hypertension, with a reported incidence of minor liver enzyme elevations of less than 2% during clinical trials. While generally considered safe, the potential for drug-induced hepatotoxicity is a rare but documented risk, leading many to ask: **Can losartan raise ALT levels?**

According to research, high doses of aspirin can cause elevated liver enzymes and hepatotoxicity, while low-dose use has demonstrated potential protective effects against certain liver conditions. The effect of aspirin on the liver is complex, depending heavily on the dosage and the patient's underlying health status.

While drug-induced liver injury (DILI) is an uncommon adverse event in the general population, some antivirals, particularly older antiretrovirals, are known to more frequently cause elevations in liver enzymes. In some instances, severe hepatotoxicity can occur, emphasizing the importance of monitoring and understanding the risks associated with these medications.

According to the drug manufacturer, Rezdiffra is typically a long-term treatment intended for adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced fibrosis. The answer to **how long do you have to take Rezdiffra** is not a fixed timeline but is a personalized decision made in consultation with a liver specialist based on individual response.